Lexicon Pharmaceuticals, Inc. (LXRX)
NCM · Healthcare · Biotechnology
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 14.2M | 5.5M | 21.1M | 692K |
| Gross Profit | 14.2M | 5.3M | 21.0M | 653K |
| Operating Income | (12.2M) | (14.8M) | (996K) | (26.5M) |
| Net Income | (12.8M) | (15.5M) | (1.0M) | (31.8M) |
| Diluted EPS | $-0.04 | $-0.04 | $0.00 | $-0.07 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 139K | 1.2M | 31.1M | 49.8M |
| Gross Profit | 139K | 1.1M | 30.5M | 49.5M |
| Operating Income | (100.8M) | (171.8M) | (197.1M) | (48.9M) |
| Net Income | (101.9M) | (177.1M) | (200.4M) | (50.3M) |
| Diluted EPS | $-0.62 | $-0.79 | $-0.63 | N/A |